New Zealand Regulator Approves MDMA for PTSD Treatment on September 4, 2026
Verified
New Zealand’s pharmaceutical regulator, Medsafe, authorized two psychiatrists to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD). Two psychiatrists in the country received permission to prescribe the substance to eligible PTSD sufferers. This regulatory move follows Australia’s 2023 approval of psychedelics for treating PTSD and depression.